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Abstract
Malignant melanoma represents the third common cause of brain metastasis, having the highest propensity to metastasize
to the brain of all primary neoplasms in adults. Since the central nervous system lacks a lymphatic system, the only
possibility for melanoma cells to reach the brain is via the blood stream and the blood-brain barrier. Despite the great
clinical importance, mechanisms of transmigration of melanoma cells through the blood-brain barrier are incompletely
understood. In order to investigate this question we have used an in vitro experimental setup based on the culture of
cerebral endothelial cells (CECs) and the A2058 and B16/F10 melanoma cell lines, respectively. Melanoma cells were able to
adhere to confluent brain endothelial cells, a process followed by elimination of protrusions and transmigration from the
luminal to the basolateral side of the endothelial monolayers. The transmigration process of certain cells was accelerated
when they were able to use the routes preformed by previously transmigrated melanoma cells. After migrating through the
endothelial monolayer several melanoma cells continued their movement beneath the endothelial cell layer. Melanoma
cells coming in contact with brain endothelial cells disrupted the tight and adherens junctions of CECs and used (at least
partially) the paracellular transmigration pathway. During this process melanoma cells produced and released large
amounts of proteolytic enzymes, mainly gelatinolytic serine proteases, including seprase. The serine protease inhibitor
PefablocH was able to decrease to 44–55% the number of melanoma cells migrating through CECs. Our results suggest that
release of serine proteases by melanoma cells and disintegration of the interendothelial junctional complex are main steps
in the formation of brain metastases in malignant melanoma.
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Introduction
Malignant melanoma is the third common cause of brain
metastasis behind lung and breast cancer, having the highest
propensity to metastasize to the brain of all primary neoplasms in
adults. Autopsy data indicate a prevalence of 55–75% of brain
metastasis in melanoma. Brain metastases contribute to death in
nearly 95% of patients with a median survival of less than one year
(for review see: [1,2]).
Since the central nervous system (CNS) lacks a lymphatic
system, tumor cells can only reach the brain parenchyma by
hematogenous metastasis formation. During this process meta-
static cells need to traverse brain endothelial cells which in turn
form the morphological basis of the blood-brain barrier (BBB).
The BBB is a complex system with the main function of regulating
the entry of blood-borne substances into the brain and thus
maintaining the homeostasis of the CNS. Cerebral endothelial
cells (CECs) – coming in contact with pericytes and astrocytes –
form a single cell layer lining the blood vessels, and are sealed with
a continuous belt of tight junctions (TJs) (for review see: [3]). TJs
regulate the paracellular permeability of the endothelial layer and
are composed of transmembrane proteins, including occludin,
claudins and junctional adhesion molecules, and cytoplasmic
plaque proteins which comprise zonula occludens proteins (ZO-1,
ZO-2) and associated molecules (for review see: [4]). Development
and maintenance of tight junctions is supported by adherens
junctions (AJs) which are located basolaterally to TJs and also form
a continuous line along cell-cell boundaries. AJs are also composed
of transmembrane proteins (cadherins) and cytoplasmic proteins
(catenins).
The process of transendothelial migration of tumor cells is
largely uncharacterized, and much of our knowledge comes from
endothelial cells of non-cerebral origin, which do not present the
special BBB phenotype. Different cell surface and adhesion
molecules, proteolytic enzymes and signaling pathways have been
shown to facilitate invasive and migratory capacities of melanoma
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cadherins [5], P-glycoprotein [6] and the Rho-ROCK/Rac
system [7–9].
However, very few experimental data are available about the
interaction of melanoma cells with brain endothelial cells. It has
been shown that the ability of melanoma cells to cross the BBB in
vitro was correlated with their melanotransferrin expression levels
at the cell surface [10]. Moreover, the fibrinolytic system was
shown to play an important role [11]. Key steps in formation of
melanoma brain metastasis were determined by in vivo real-time
imaging and proved to be the following: arrest at vascular branch
points, extravasation, persistent close contacts to microvessels and
perivascular growth by vessel cooption [12].
In physiological conditions the endothelial barrier in the brain is
so tight that not even ions can freely pass from one side to the
other, therefore it is of special interest to elucidate how metastatic
cells can migrate through the BBB. Moreover, taking into account
the very poor prognosis and the limited therapeutical possibilities,
it is of primordial importance to prevent melanoma brain
metastasis, and therefore to understand the interaction between
melanoma cells and CECs.
Results
Transmigration of melanoma cells through the in vitro
blood-brain barrier model
In order to study the routes and mechanisms of transendothelial
migration of melanoma cells we have developed an in vitro model
system based on the culture of cerebral endothelial cells (primary
brain endothelial cells isolated from rat: RBECs and a human
cerebral microvascular endothelial cell line: hCMEC/D3, shortly
D3) and two melanoma cell lines (the human A2058 and the
murine B16/F10).
We have observed that A2058 and B16/F10 melanoma cells
were able to adhere to RBEC or D3 monolayers in a time
dependent manner (Fig. 1). Melanoma cells started to attach to
cerebral endothelial cells already after 15 min, process accelerated
between 30–120 min. When parallely the same number of A2058
or B16/F10 cells was plated onto confluent brain endothelial
monolayers, B16/F10 cells attached in a higher number to the
endothelium than A2058 cells. Comparing the two endothelial
monolayers, both melanoma cell types adhered much easier to the
human cell line than to primary rat cells.
We have constructed a transmigration experimental setup
(described in details in the Material and methods section) which
consists of brain endothelial cells cultured on large pore size
(8 mm) filter inserts. In our experience smaller pore sizes
(including 3 mm) restrict the majority of tumor cells migrated
through the endothelial cell layer to migrate onto the lower
surface of the filter (not shown). In all cases we have verified the
confluency of control endothelial monolayers by TEER mea-
surements both at the beginning and at the end of the
experiments and by immunofluorescence stainings of tight
junction proteins. Fluorescently labeled melanoma cells were
plated onto the apical side of the endothelial monolayer in a ratio
of 9?10
4 melanoma cells/cm
2, which is lower than the number of
tumor cells used in the literature in similar assays [13,14]. We
have also verified that melanoma cells labeled with Oregon
GreenH 488 carboxylic acid diacetate succinimidyl ester (shortly:
OG) or CellTracker
TM Blue did not stain the endothelial cells,
not even after fixation. In our experience this was not always true
when Hoechst 33342 was used. In the 5 h time frame
proliferation of both cell lines was very low (not shown) and
therefore did not affect the results of the transmigration assay.
This setup makes possible the quantitative analysis of the
transendothelial migration of tumor cells.
Both melanoma cell lines were able to cross the endothelial cell
layer and migrate through the pores of the filter. Melanoma cells
tended to accumulate on the lower side of the filter, where they
could be easily counted. Transmigration of melanoma cells
Figure 1. Adhesion of melanoma cells to brain endothelial cells. Fluorescently labeled melanoma cells (A2058 or B16/F10) (2.5?10
4/cm
2) were
plated onto confluent CECs (RBEC or D3) and left for different time intervals. After washing of non-adherent cells, attached melanoma cells were
counted.
doi:10.1371/journal.pone.0020758.g001
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confocal microscopy images as well. Endothelial cells were grown
on coverslips and melanoma cells were plated onto the apical
(luminal) side of the monolayer (‘‘above’’ endothelial cells).
Melanoma cells reaching the basolateral side of endothelial cells
could be observed closer to the coverslip than the tight junctions of
endothelial cells (‘‘beneath’’ endothelial cells) (Fig. 2).
Performing time-lapse video (Video S1 and S2) we have
observed that melanoma cells plated on a confluent brain
endothelial monolayer started to eliminate protrusions at about
15–30 min after coming in contact with the endothelial cells. After
about 60–120 min some melanoma cells started to change their
morphology, becoming flattened and elongated, and completed
the transmigration process in 15–30 min (S1 cell no.: 1 and 2a, S2
cell no.: 2 and 3). Other melanoma cells were not able to migrate
through the endothelial monolayer in a 3–6 h time frame. Certain
tumor cells covered several hundred micrometer long distances,
stopping in different places on the apical side of the endothelial cell
layer, without performing a successful transmigration (S2 cell no.:
1). We observed that the transmigration process of certain cells was
accelerated when they were able to use the routes preformed by
previously transmigrated melanoma cells (S1 cell no.: 3).
Moreover, after migrating through the endothelial monolayer,
melanoma cells did not remain in close proximity to the pore of
transmigration but continued their movement beneath the
endothelial cell layer (S1 cell no.: 1, S2 cell no.: 2 and 3).
In order to investigate the possible effects of melanoma cells on
the integrity of the barrier, we have measured the transendothelial
electrical resistance (TEER) of CECs (Fig. 3). A2058 cells reduced
the resistance of the endothelium in a time dependent manner, the
decrease reaching 30% at 24 h; while B16/F10 melanoma cells
induced a statistically significant decrease in TEER already at 5 h.
Moreover, melanoma cells induced a 4.7 times increase in the
number of apoptotic brain endothelial cells (from 1.7% in the
absence of A2058 cells to 7.54%) as visualized by anti-cleaved
caspase-3 staining (Fig. 4). No difference in the number of
apoptotic melanoma cells was observed in the presence or absence
of CECs (not shown).
Paracellular transmigration of melanoma cells through
the BBB
It is well documented that leukocytes are able to use both the
paracellular (through the interendothelial junctions) and the
transcellular (through individual endothelial cells) transmigration
pathways (for review see: [15,16]). However, much less is known
about the routes of transendothelial migration of tumor cells. Since
the drop in the transendothelial electrical resistance of the cells
indicated a damage of the tight junctions, in our experiments we
have focused on the investigation of the paracellular migration of
melanoma cells. Moreover, on sections examined by transmission
electron microscopy we have found melanoma cells attached to
the junctional sites of endothelial cells, raising the possibility that
melanoma cells tended to migrate between two endothelial cells
(Fig. 5).
Therefore we have examined changes in the localization and
expression of the main tight junction proteins. Fig. 6 shows that
melanoma cells tended to adhere to brain endothelial cells in small
clusters and were able to disrupt the continuous membrane
staining of transmembrane TJ proteins (occludin and claudin-5),
and the cytoplasmic plaque protein ZO-1. The same changes were
observed in case of the adherens junction protein b-catenin (not
shown). At 2 h co-culture of melanoma cells with brain endothelial
monolayers claudin-5 disappeared totally from the region where
melanoma clusters adhered to endothelial cells (Fig. 6 A first
panel). At the same place ZO-1 staining was only partly disrupted
(Fig. 6 A second panel). This suggests that the first affected TJ
proteins were transmembrane proteins. At 5 h after plating of
melanoma cells onto CECs no difference was observed between
the localization changes of transmembrane and plaque proteins of
tight junctions. Small clusters of A2058 cells adhered to CECs
induced the disappearance of claudin-5, ZO-1 (Fig. 6 B) and
occludin (Fig. 6 C) from the intercellular contacts. We could
observe the same phenomenon in case of B16/F10 cells (Fig. 6 D).
These results suggest that melanoma cells are able to take the
paracellular pathway of transmigration. This was also supported
by our Western-blot experiments (Fig. 7). As expected, neither
A2058 nor B16/F10 cells expressed claudin-5 or occludin, which
were present in both RBEC and D3 brain endothelial cells. The
claudin-5 signal was strongly decreased by both melanoma cell
lines in RBECs (Fig. 7 A) and disappeared completely from D3
cells (Fig. 7 B), while melanoma conditioned media induced a less
pronounced effect. Similar tendencies could be observed in case of
occludin (Fig. 7 C, D), where the degradation products could also
be visualized in D3 cells in the presence of B16/F10 cells or
conditioned medium (Fig. 7 D).
Our data unequivocally show that melanoma cells are able to
disrupt the junctions of CECs and transmigrate through the
paracellular pathway. However, these results cannot exclude the
possibility that melanoma cells take the transcellular pathway as
well.
Figure 2. Migration of melanoma cells from the apical to the
basolateral side of CECs. RBECs were grown on glass coverslips.
A2058 melanoma cells labeled with OG were plated onto confluent
endothelial monolayers. After 5 h cells were washed, fixed and tight
junctions were stained with anti-ZO-1 antibody (red). Samples were
analysed by confocal laser scanning microscopy. A: xy-stack at the level
of the green lines on B and C. B, C: z-stacks along the vertical and
horizontal line, respectively on A.
doi:10.1371/journal.pone.0020758.g002
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Asa nextstep we haveinvestigatedtheproductionofproteasesby
A2058 and B16/F10melanomacells inthe presence and absenceof
brain endothelial cells by gelatin zymography. Proteolytic enzymes
both released in the culture medium (Fig. 8 A) and their membrane
bound forms (Triton X-114 fraction) (Fig. 8 B) were analyzed. We
have observed that both melanoma cell lines expressed several
gelatinolytic proteases and the amount of these was increased when
melanoma cells were plated onto brain endothelial cells. Unexpect-
edly, the gelatinolytic bands did not disappear in the presence of the
matrix metalloproteinase inhibitor EDTA (Fig. 8 A, B). Addition of
E-64, an irreversible, potent and highly selective cysteine protease
inhibitor had no effect on the release of gelatinolytic enzymes.
However, addition of PefablocH, an irreversible serine protease
inhibitor, induced the almost complete disappearance of the
proteolytic bands from both the supernatant and the cell lysate
fraction. This indicates that gelatinolytic serine proteases are
produced by melanoma cells in large amounts especially when
coming in contact with endothelial cells.
We have also observed that presence of PefablocH significantly
reduced the transendothelial migration rate of both A2058 and
B16/F10 melanoma cells (to 5864% in case of A2058 and to
44611% in case of B16/F10) (Fig. 8 C, D). Migration of
melanoma cells in the absence of endothelial cells was not affected
by PefablocH as assessed by the wound assay (not shown).
As a next step we wanted to identify which serine proteases are
expressed by melanoma cells. One of the most well characterized
serine protease with gelatinolytic activity is seprase, which has
already been shown to be activated in tumors [17]. As indicated on
Fig. 8 B, A2058 but not B16/F10 melanoma cells express a
170 kDa gelatinolytic membrane-bound serine protease. After
silencing of the seprase gene the 170 kDa gelatinolytic band
disappeared from the zymography gel (Fig. 9 A). Therefore, we
could identify seprase as one of the gelatinolytic serine proteases
expressed by A2058 cells. Silencing of seprase in A2058 melanoma
cells induced a more than 20% decrease in the number of cells
transmigrated through brain endothelial cells (Fig. 9 B). These
data suggest that seprase plays an important, but not a unique role
among proteases involved in the transmigration of melanoma cells
through the BBB.
Discussion
The CNS is a common site for melanoma metastasis.
Development of brain metastases is of very poor prognosis despite
extensive therapeutical efforts. Therefore, it is very important to
understand the mechanisms of migration of tumor cells through
the BBB, which could eventually help to develop preventive
strategies against the formation of melanoma brain metastasis.
In order to study the mechanisms of transendothelial migration
of melanoma cells, we have developed an in vitro model system.
Figure 3. Changes in the transendothelial electrical resistance in the presence of melanoma cells. RBECs were grown on semipermeable
filters with 0.4 mm pore size. TEER was followed using the CellZscope system. N=2, *=P,0.05 as assessed by ANOVA and Bonferroni’s post hoc test.
doi:10.1371/journal.pone.0020758.g003
Figure 4. Induction of endothelial apoptosis by melanoma
cells. RBECs were cultured on glass coverslips. A2058 melanoma cells
labeled with CellTracker
TM Blue were plated onto confluent endothelial
monolayers. After 24 h cells were washed and fixed. Tight junctions
were stained with anti-ZO-1 antibody (marker of endothelial cells), while
apoptotic cells were visualized using anti-cleaved caspase-3 antibody.
Apoptotic endothelial cells were counted. N=2, *=P,0.05 as assessed
by Student’s t-test.
doi:10.1371/journal.pone.0020758.g004
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vitro models are becoming more and more used prior to or parallel
with in vivo models. Moreover, since rodents rarely develop
cerebral metastases of melanoma, inoculation of tumor cells into
the systemic circulation or into the brain is used to study this
question. These in vivo systems however, are not suitable to study
specific mechanisms regarding the migration of tumor cells
through the BBB. The in vitro approach makes possible the
detailed analysis of the mechanisms of transmigration of
melanoma cells through brain endothelial monolayers, which
cannot be readily approached in vivo because of the complexity of
the system. Similar systems have been widely used to study the
transmigration of leukocytes through endothelial barriers [18,19].
The in vitro BBB model used in our experiments is based on the
culture of primary rat brain endothelial cells (RBECs) or the
human cerebral endothelial cell line hCMEC/D3 (D3). RBECs in
our culture system maintain the main characteristics of the brain
endothelium in vivo, such as expression of von Willebrand factor,
presence of a continuous line of tight junctions, high transen-
dothelial electrical resistance (TEER) and low permeability values
and high activity of P-glycoprotein. However, the fact that rodents
develop in very rare instances spontaneous melanoma brain
metastases [20] points towards significant differences between the
human and animal disease. This makes necessary the use of
human endothelial cells despite their inferior permeability
characteristics. Moreover, it has been shown that human
melanoma cells injected into mice give spontaneous CNS
metastasis [12,21], therefore a xenogeneic model can also be
accepted. The hCMEC/D3 cell line [22] is the most well
characterized human brain endothelial cell line, which has been
widely used as a human BBB model [23,24].
We have used the A2058 cell line, which has been shown to
produce brain metastasis when injected into immunodeficient
mice [12]. We have also used murine B16/F10 cells, which
initially were adapted to form lung metastasis; however, they are
able to form brain metastases as well [25,26].
Our results show that melanoma cells attached in a higher
number to D3 cells than to RBECs. This might be due to the
difference in the human and rat adhesion molecules, but also to
the lower tightness of the barrier formed by the human cell line.
Our time-lapse video suggests that transmigrated melanoma
cells tended to attract other melanoma cells to migrate through the
endothelial cell layer at the same site. We could also visualize that
transmigrated melanoma cells moved along the basolateral side of
the endothelial monolayer. This is in accordance with the
observations of Lu et al. [27] who described that breast cancer
cells injected intracardially into mice extravasated into the brain
and aligned themselves along the blood vessels, on the basolateral
side of endothelial cells, suggesting that the tumor cells migrated
along the vasculature. This ‘‘pericyte-like’’ position of transmi-
grated tumor cells was also observed by Kienast et al. [12] using in
vivo multiphoton laser scanning microscopy. They have described
that melanoma and lung cancer cells could only proliferate in the
brain if they maintained a direct contact to the abluminal side of
endothelial cells of cerebral capillaries. These results might raise
the possibility of a hiding mechanism of tumor cells behind the
defense lines (especially the MDR-MRP systems) of the BBB.
During transmigration melanoma cells damaged the integrity of
the endothelial monolayer, which is supported by the decrease of
TEER and the presence of apoptotic endothelial cells. These
observations are in accordance with previous results showing that
– in contrast to leukocytes – tumor cells do not leave the
endothelium intact after diapedesis [28].
Regarding the routes of transmigration, there are two
theoretical possibilities, which have been intensively studied in
the case of leukocytes: the paracellular pathway (through the
interendothelial junctions) and the transcellular one (through
single endothelial cells). A large number of in vitro and in vivo
studies have demonstrated that leukocyte diapedesis can occur
either by forming a paracellular gap or via the formation of a
transcellular pore (for review see: [15,16]). The phases and
molecular mechanisms involved in the extravasation of leukocytes
have also been largely characterized. Since the CNS is an
immunologically privileged site, transendothelial migration of
leukocytes through the BBB is practically limited to neuroin-
flammation. Mononuclear cells can traverse the inflamed BBB
both through the tight junctions (paracellular pathway) [29] and
transcellularly [30].
However, much less is known about the extravasation of tumor
cells (for review see: [28]). It has been shown that – similarly to
leukocytes – breast cancer cells are able to use both the para- and
the transcellular transmigration routes [31]. Here we show that
melanoma cells are able to disrupt interendothelial junctions and
to migrate through the paracellular pathway.
One of the key steps of successful metastasis formation is the
proteolytic degradation of the extracellular matrix. This process is
important not only during the invasion of the surrounding tissue
by the primary tumor and the step of intravasation, but also during
extravasation. Moreover, tight junction proteins are also targets of
proteolytic degradation [29]. The plasminogen/plasmin system
Figure 5. Adhesion of melanoma cells to interendothelial junctions. RBECs were grown on 8 mm pore size filter inserts. After reaching
confluency A2058 cells were plated into the upper chamber and left for 5 h. Samples were fixed and 60–70 nm sections were prepared for electron
microscopy. Arrow indicates interendothelial cell contact site. M=melanoma cell, E=endothelial cell. Scale bar=10 mm.
doi:10.1371/journal.pone.0020758.g005
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through brain endothelial cells both in vivo and in vitro [11].
Melanoma cells are able to express several types of proteases
including uPA [32], seprase [33,34] and matrix metalloproteinases
[35–37] which have been shown to promote their invasiveness.
Our results show that during the transendothelial migration
process melanoma cells express on their membranes and release
large amounts of proteases with gelatinolytic activity. Much to our
surprise the majority of these enzymes proved to be not matrix
metalloproteinases, since addition of EDTA to the incubation
buffer did not decrease the number and intensity of the proteolytic
bands. In contrast, after addition of the irreversible serine protease
inhibitor PefablocH to the culture medium the gelatinolytic bands
almost completely disappeared and the number of melanoma cells
migrated through the brain endothelial monolayer decreased
significantly.
We have examined whether among these gelatinolytic serine
proteases seprase and/or its degradation products are present.
Seprase (surface expressed protease) or FAPa (fibroblast activa-
tion protein a) is a type II transmembrane glycoprotein, originally
identified in LOX melanoma cells [34], contributing to the
invasiveness of melanoma and carcinoma cells (for review see:
[38]). It has two types of EDTA-resistant protease activities:
dipeptidyl peptidase and a 170 kDa gelatinase activity. Seprase
has been identified as a potential marker protease of invasiveness,
localized on invadopodia of malignant melanoma cells [33].
Seprase shares homology with dipeptidyl peptidase IV (DPPIV),
however, this latter is expressed by normal melanocytes, epithelial
and other cells, while seprase is characteristic for tumor and
proliferating mesenchymal cells [39,40]. Using PCR we have
found that human brain endothelial D3 cells express DPPIV, but
do not express seprase, while A2058 human melanoma cells
express seprase, but not DPPIV (not shown). By gelatin
zymography coupled with gene silencing we have shown that
A2058, but not B16/F10 cells express seprase in the Triton X-
114-extractable membrane fraction. However, several other
gelatinolytic serine proteases were expressed by both melanoma
cell lines which did not disappear after seprase-silencing.
Accordingly, silencing of seprase reduced to a lesser extent the
number of transendothelially migrated melanoma cells compared
to PefablocH. The identity of these enzymes still needs to be
elucidated.
In conclusion, our in vitro results suggest that during brain
metastasis formation melanoma cells damage the integrity of
the BBB by inducing apoptosis of endothelial cells and by
disrupting the continuity of the tight junctions. Transmigrating
melanoma cells are able to use the paracellular pathway to
overcome the cerebral endothelial monolayer and seem to be
able to hide behind the defense lines of the BBB. During their
transendothelial migration melanoma cells produce serine
proteases capable of degrading the components of the
basement membrane of capillaries, and inhibition of these
proteases can significantly reduce the number of extravasating
melanoma cells.
Figure 7. Changes in the total amount of endothelial junctional proteins in the presence of melanoma cells or melanoma-released
factors. Melanoma cells or melanoma conditioned media were placed onto confluent brain endothelial cells (A, C: RBEC; B, D: D3) and the amount of
claudin-5 (A, B) or occludin (C, D) was assessed by Western-blot analysis.
doi:10.1371/journal.pone.0020758.g007
Figure 6. Disruption of interendothelial tight junctions induced by melanoma cells. Fluorescently labeled (A, B: CellTracker
TM Blue, C, D:
OG) melanoma cells (A, B, C: A2058 or D: B16/F10) were plated onto confluent brain endothelial cells (RBEC) and left for 2 (A) or 5 h (B–D). After
washing of non-attached melanoma cells samples were fixed and stained for claudin-5, ZO-1 or occludin. Arrows indicate sites of disrupted junctions.
Scale bar=50 mm.
doi:10.1371/journal.pone.0020758.g006
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Cell culture
A2058 human melanoma cells (obtained from the European
Collection of Cell Cultures) were maintained in MEM (Sigma)
supplemented with 5% FBS (Lonza) and Glutamax (Invitrogen).
B16/F10 murine melanoma cells were kept in RPMI medium
(Sigma) supplemented with 5% FBS (Lonza) and Glutamax. The
hCMEC/D3 [22] human cerebral endothelial cells (shortly D3)
were grown on rat tail collagen-coated dishes in EBM-2 medium
(Lonza) supplemented with EGM-2 Bullet Kit (Lonza) and 2.5%
FBS (Sigma).
Primary rat brain endothelial cells (RBECs) were isolated
from 2-week old rats, as described previously [41,42]. Briefly,
after removal of meninges cerebral cortices were cut into small
pieces and digested with 1 mg/ml collagenase type 2 (Sigma)
for 75 min at 37uC. After separation of myelin by centrifuga-
tion in 20% BSA, a second digestion was performed with 1 mg/
ml collagenase/dispase (Roche) for 50 min at 37uC. Microves-
sel fragments were collected after 10 min 1000Ng centrifugation
on Percoll (Sigma) gradient, and plated onto fibronectin/
collagen-coated dishes. Endothelial cells growing out of the
microvessels were cultured in DMEM/F12 (Invitrogen), 10%
plasma-derived serum (PDS, First Link) and growth factors. In
the first two days, 4 mg/ml puromycin was added to remove
contaminating cells.
Isolation of primary cerebral endothelial cells was carried out in
strict accordance with the national and international recommen-
dations for the care and use of laboratory animals. The protocol
was approved by the Regional Animal Health and Food Control
Station of Csongra ´d County (Permit Number: XVI./03839/001/
2006). All efforts were made to minimize suffering.
Figure 8. Role of gelatinolytic serine proteases produced by melanoma cells. A, B: Melanoma cells were plated onto confluent monolayers
of cerebral endothelial cells or into empty culture dishes in serum-free medium in the presence or absence of E64 or PefablocH and left for 5 h.
Culture media were collected and cells were lysed in Triton X-114 containing buffer. Samples were electrophoresed in non-denaturing conditions and
the gels were incubated in EDTA-containing buffer for 2 days. Proteolytic bands of culture media (A) or cell lysates (B) were visualized by Coomassie
blue staining. C, D: RBEC were grown until confluency on 8 mm pore size filter inserts. Fluorescently labeled melanoma cells (C: A2058, D: B16/F10)
were plated into the upper chamber in the presence or absence of PefablocH and left for 5 h. Cells from the upper chamber were removed using a
cotton swab, and melanoma cells migrated through the endothelial cell layer and the pores of the filter were counted. N=3, *=P,0.05 as assessed
by Student’s t-test.
doi:10.1371/journal.pone.0020758.g008
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D3 cells were grown in 6 cm culture dishes. After reaching
confluency 10
6 A2058 cells were plated onto the endothelial cell
layer and phase contrast images were taken every 5 min using a
digital camera (Spot RT KE, Diagnostic Instruments) connected
to the microscope (Nikon Eclipse TE2000U). Experiments were
performed at 37uC. Serial images were converted to video stream
with VirtualDub version 1.9.10. Xvid MPEG4 video codec version
1.2.2 was used for video compression.
Adhesion experiments
Brain endothelial cells (RBEC or D3) were grown until
confluency in 24-well plates. Melanoma cells (A2058 or B16/
F10) were fluorescently labeled using Oregon GreenH 488
carboxylic acid diacetate succinimidyl ester (shortly: OG, Invitro-
gen) using the protocol supplied by the manufacturer. 5?10
4
melanoma cells/well were loaded onto the endothelial cells in
serum-free medium and left for different time intervals. Non-
attached cells were washed and remaining cells were fixed using
ethanol/acetic acid (95/5) at 220uC for 5 min. Melanoma cells
adhered to endothelial cells were photographed and counted using
the Image-Pro Plus software.
Transmigration experimental setup
For transmigration experiments primary RBECs were gently
trypsinized and passed onto fibronectin/collagen-coated filter
inserts (8 mm pore size, 1.13 cm
2, Millipore) which were placed in
12-well plates. After reaching confluency, endothelial cells were
supplemented with 550 nM hydrocortisone, 250 mM CPT-cAMP
(Sigma) and 17.5 mM RO-201724 (Roche) from the apical side
and astrocyte conditioned medium from the basolateral side for
24 h in order to tighten the junctions. This way we could achieve
high transendothelial electrical resistance values.
10
5 OG-labeled melanoma cells were plated into the upper
compartment onto the endothelial monolayer in serum-free
medium. The lower compartment was loaded with serum-free
medium containing 100 mg/ml type I collagen. PefablocH was
added in a concentration of 200 mM to both the apical and
basolateral side. Cells were left for 5 h, followed by fixation with
ethanol/acetic acid. Cells from the upper compartment were
removed with a cotton swab and melanoma cells migrated through
the endothelial monolayer and the pores of the filter were counted.
Immunofluorescence and laser confocal microscopy
RBECs (P0 or P1) were cultured until confluency on collagen/
fibronectin-coated glass coverslips. Melanoma cells (A2058 or
B16/F10) were fluorescently labeled using CellTracker
TM Blue
CMAC (Invitrogen) or OG and plated onto the endothelial
monolayer. After 5 h cells were washed and fixed with ethanol/
acetic acid. After blocking with 3% BSA (Sigma) for 30 min,
coverslips were incubated with primary antibodies against
occludin, claudin-5 or ZO-1 (Zymed) or cleaved caspase-3 (Cell
Signaling). The staining was visualized using Cy3- or Cy5-
conjugated secondary antibodies. Coverslips were mounted in
anti-fading embedding medium (Biomeda) and the distribution of
the signal was studied using a fluorescence microscope.
Three dimensional optical sectioning was performed using an
Olympus Fluoview FV1000 confocal laser scanning microscope.
Microscope configuration was the following: Objective lens:
UPLSAPO 60 x oil immersion objective (N.A:1.35); XY scanning
dimensions: 512?512 pixels with 0.094 mm/pixel; Z dimension: 15
sections with 0.47 mm/slice; sampling speed: 2 ms/pixel; confocal
aperture: 152 mm; zoom: 4.4 x; scanning mode: sequential
unidirectional; excitation: 488 nm (OG) and 543 nm (Cy3); laser
transmissivity: 9% and 20% were used for OG and Cy3,
respectively; main dichroic beamsplitter: DM405/488/543; inter-
mediate dichroic beamsplitter: SDM 560; OG was detected
between 500–530 nm, Cy3 was detected between 555–655 nm
with spectral detectors. Using the Olympus Fluoview software
(version 1.7.2.2), OG and Cy3 images were pseudocolored green
and red, respectively.
Measurement of transendothelial electrical resistance
(TEER)
RBECs were grown on collagen/fibronectin-coated semiper-
meable filters (0.4 mm pore size, 1.12 cm
2, Costar Corning
Figure 9. Role of seprase in the transmigration of A2058 cells through brain endothelial cells. A: Seprase was silenced in A2058 cells (fold
change=0.09 compared to scrambled RNA-transfected cells, determined by real-time PCR). Melanoma cells were plated onto confluent monolayers
of cerebral endothelial cells or into empty culture dishes in serum-free medium and left for 5 h. Cells were lysed in Triton X-114 containing buffer.
Zymography was performed in the presence of EDTA. Arrow indicates seprase. B: Seprase-silenced or scrambled RNA-transfected cells were plated
onto confluent RBECs grown on 8 mm pore size filter inserts. Transmigration assay was performed and melanoma cells reaching the bottom of the
filter inserts were counted. N=3, *=P,0.05 as assessed by Student’s t-test.
doi:10.1371/journal.pone.0020758.g009
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monolayer was supplied with 550 nM hydrocortisone, 250 mM
CPT-cAMP (Sigma) and 17.5 mM RO-201724 (Roche) and
placed into the wells of the CellZscopeH instrument (nanoAnaly-
tics) containing astrocyte conditioned medium. After TEER had
reached plateau, 10
5 melanoma cells were plated into the apical
chamber and TEER was followed for 24 h.
Transmission electron microscopy
RBECs were cultured on 8 mm pore size filter inserts. 2?10
5
A2058 melanoma cells were plated onto the endothelial
monolayer and left for 5 h. After washing in PBS cells were fixed
in 1% formaldehyde and 1% glutaraldehyde in 0.1 M phosphate
buffer and postfixed in 1% osmium tetroxide in 0.1 M phosphate
buffer. Fixed cells were dehydrated and embedded in Spurr resin.
Thin sections were cut using a Leica ultramicrotome, contrasted
with uranyl acetate and lead citrate and examined using a Zeiss
902 electron microscope.
Western-blot analysis
Melanoma cells were plated onto confluent brain endothelial
cells (RBEC or D3) in serum-free medium and left for 24 h. Cells
were washed with PBS and scraped into ice-cold lysis buffer
(20 mM Tris, 150 mM NaCl, 0.5% Triton X-100, 1% sodium
deoxycholate, 0.1% sodium dodecyl sulphate, 1 mM sodium
vanadate, 10 mM NaF, 1 mM EDTA, 1 mM PefablocH) and
incubated on ice for 30 min. Lysates were clarified by centrifu-
gation at 10,000Ng for 10 min at 4uC. Proteins were electropho-
resed and blotted onto PVDF (Millipore) or nitrocellulose
(Whatman) membranes. Blocking the nonspecific binding capacity
of the membranes was carried out at room temperature for 30 min
in TBS-T containing either 5% casein (nonfat milk powder) or 3%
BSA in the case of claudin-5. Anti-claudin-5 (Zymed) and anti-
occludin (Transduction Laboratories) primary antibodies were
used. After washing the membranes in TBS-T, blots were
incubated with the secondary antibodies (Pierce) diluted in TBS-
T. The immunoreaction was visualized using the Immobilon
Western Chemiluminescent HRP Substrate (Millipore) on X-ray
film (Agfa).
Zymography
D3 cells were grown in 12-well plates. 2?10
5 A2058 melanoma
cells were plated onto the endothelial monolayer in serum-free
medium and left for 5 h. Culture media were collected, clarified by
centrifugation at 10,000?g for 10 min on 4uC and prepared in
mercaptoethanol-free Laemmli buffer. Cells were washed and
lysed in ice cold TBS containing 1.5% Triton X-114. Samples
were centrifuged at 4uC and the supernatants were placed to 37uC
for 5 min. After centrifugation at room temperature for 2 min the
upper aqueous phase was thrown away and the membrane
fraction was dissolved in mercaptoethanol-free Laemmli buffer.
Samples were electrophoresed under non-denaturing conditions in
a polyacrylamide gel containing 1.5 mg/ml gelatin. Gels were
washed two times in 2.5% Triton X-100 and two times in water
and incubated for two days at 37uC in a buffer containing 50 mM
Tris pH=7.4, 5 mM CaCl2, 1 mM ZnSO4, 1 mM MgCl2 and
0.2 M NaCl or 50 mM Tris pH=7.4, 0.2 M NaCl and 5 mM
EDTA. Gels were stained with Coomassie BBR-250 for 20 min
and destained using 10% methanol and 10% acetic acid until the
gelatinolytic bands became visible.
Specific knockdown of seprase by RNA interference
Stealth
TM siRNA duplex oligoribonucleotides were designed
using Invitrogen BLOCK-iT
TM RNAi designer and were
purchased from Invitrogen. The sequences used were as follows:
sense: 59- AAGAAGUGUGUUACUUGCCAUCUAA-39; anti-
sense: 59- UUAGAUGGCAAGUAACACACUUCUU -39. As co-
ntrol non-targeting RNA we have used the following scrambled
oligonucleotides: sense: 59-GACGUAGAGAGAGUUCCGACA-
UACA-39 and antisense: 59-UGUAUGUCGGAACUCUCUC-
UACGUC-39. Briefly, A2058 cells were plated at 50% confluency.
Transfection of oligonucleotides was performed in OptiMEM
medium containing 10 nM RNA and Lipofectamine
TM RNAi-
MAX reagent (Invitrogen) following the manufacturer’s instruc-
tions. After 8 h the medium was changed to regular culture
medium. In order to increase the efficiency, a second transfection
was performed the following day. Cells were used 24 h after the
second transfection. At the same time transfection efficiency was
analyzed by real-time PCR.
Supporting Information
Video S1 Time-lapse video imaging of transmigration
of melanoma cells through brain endothelial monolay-
ers. A2058 cells were plated onto confluent D3 cultures. Phase
contrast images were taken at every 5 min from the same regions
and time-lapse videos were constructed. 1 s in the video file
corresponds to 50 min in real time.
(AVI)
Video S2 Time-lapse video imaging of transmigration
of melanoma cells through brain endothelial monolay-
ers. A2058 cells were plated onto confluent D3 cultures. Phase
contrast images were taken at every 5 min from the same regions
and time-lapse videos were constructed. 1 s in the video file
corresponds to 50 min in real time.
(AVI)
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